| 1 |
34025432 | Effects of Antiarrhythmic Drugs on hERG Gating in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes From a Patient With Short QT Syndrome Type 1. | 2021 |
1 |
| 2 |
30582453 | Patient-Specific and Gene-Corrected Induced Pluripotent Stem Cell-Derived Cardiomyocytes Elucidate Single-Cell Phenotype of Short QT Syndrome. | 2019 Jan 4 |
2 |
| 3 |
31946488 | Pharmacotherapeutic Effects of Quinidine on Short QT Syndrome by Using Purkinje-Ventricle Model: A Simulation Study. | 2019 Jul |
2 |
| 4 |
30687112 | In silico Assessment of Pharmacotherapy for Human Atrial Patho-Electrophysiology Associated With hERG-Linked Short QT Syndrome. | 2018 |
1 |
| 5 |
28632743 | In silico assessment of the effects of quinidine, disopyramide and E-4031 on short QT syndrome variant 1 in the human ventricles. | 2017 |
7 |
| 6 |
25790957 | The interaction between delayed rectifier channel alpha-subunits does not involve hetero-tetramer formation. | 2015 Sep |
1 |
| 7 |
21130771 | A novel mutation in the KCNH2 gene associated with short QT syndrome. | 2011 Mar |
1 |
| 8 |
19528813 | The organic cation transporter, OCTN1, expressed in the human heart, potentiates antagonism of the HERG potassium channel. | 2009 Jul |
1 |
| 9 |
19617705 | Extracellular potassium dependency of block of HERG by quinidine and cisapride is primarily determined by the permeant ion and not by inactivation. | 2009 Jul-Aug |
4 |
| 10 |
18057887 | Extracellular acidification and hyperkalemia induce changes in HERG inhibition by ibutilide. | 2008 |
1 |
| 11 |
16960444 | The effect of high extracellular potassium on IKr inhibition by anti-arrhythmic agents. | 2007 |
2 |
| 12 |
17711440 | In vivo effects of mutant HERG K+ channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study. | 2007 Nov |
1 |
| 13 |
16842817 | Disopyramide is an effective inhibitor of mutant HERG K+ channels involved in variant 1 short QT syndrome. | 2006 Sep |
2 |
| 14 |
16942825 | Short QT syndrome: a case report and review of literature. | 2006 Oct |
2 |
| 15 |
15673388 | Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. | 2005 Jan |
4 |
| 16 |
15821840 | The influence of extracellular acidosis on the effect of IKr blockers. | 2005 Mar |
2 |
| 17 |
16041196 | A mechanism for the potential proarrhythmic effect of acidosis, bradycardia, and hypokalemia on the blockade of human ether-a-go-go-related gene (HERG) channels. | 2005 Jul-Aug |
4 |
| 18 |
16226079 | Short QT syndrome. Genotype-phenotype correlations. | 2005 Oct |
2 |
| 19 |
15125690 | Acidification alters antiarrhythmic drug blockade of the ether-a-go-go-related Gene (HERG) Channels. | 2004 May |
2 |
| 20 |
15189761 | Comparison of kinetic properties of quinidine and dofetilide block of HERG channels. | 2004 Jun 16 |
2 |
| 21 |
12695533 | Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. | 2003 May |
4 |
| 22 |
14525949 | The IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. | 2003 Dec |
1 |
| 23 |
12086981 | Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. | 2002 Jul |
2 |
| 24 |
11602243 | An amino acid residue whose change by mutation affects drug binding to the HERG channel. | 2001 Oct 12 |
1 |
| 25 |
10028924 | Modulation of HERG potassium channels by extracellular magnesium and quinidine. | 1999 Feb |
4 |